Hjem › Blærekreft › Oklahoma › Oklahoma City
Kliniske studier for Blærekreft i Oklahoma City, OK
11 studier for Blærekreft søker deltakere på steder i og rundt Oklahoma City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruttererFase 1
- University of Oklahoma - Health Sciences Center, Oklahoma City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RekruttererFase 2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RekruttererObservasjonsstudie
- Mercy Hospital - OKC, Oklahoma City
Blærekreft-studier i andre byer
- New York City, NY35 studier
- Nashville, TN31 studier
- Houston, TX31 studier
- Dallas, TX27 studier
- Boston, MA26 studier
- Washington, DC26 studier
- Los Angeles, CA24 studier
- Baltimore, MD24 studier
- St. Louis, MO22 studier
- Philadelphia, PA21 studier
- Seattle, WA21 studier
- Edison, NJ21 studier
Andre studier i Oklahoma City
- Ikke-småcellet lungekreft28 studier
- Eggstokkreft28 studier
- Endometriekreft25 studier
- Kolorektal kreft22 studier
- Prostatakreft21 studier
- Lungekreft19 studier
- Brystkreft17 studier
- Metastatisk kreft15 studier
- Kreft (alle typer)14 studier
- Akut myelogen leukemi14 studier
- Plateepitelcancer i hode og hals13 studier
- Pankreaskreft11 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.